Absolute increase in 30-day relapse risk associated with the second or third vaccine dose is small
AUA: Kidney Transplants From COVID-19-Infected Donors Are Safe
Recipient outcomes similar to kidneys from noninfected donors
Dapagliflozin Well Tolerated in COVID-19 Patients, Regardless of eGFR
Effects of dapagliflozin on primary and secondary outcomes consistent for those with eGFR <60 and ≥60 mL/min per 1.73 m2
Fourth Vaccine Dose May Up COVID-19 Immunity in Kidney Transplant Recipients
Fourth dose of mRNA vaccine increased antispike IgG titers in some kidney transplant recipients with weak serologic response after three doses
Vaccinated Kidney Transplant Recipients Vulnerable to SARS-CoV-2 Variants
After two-dose vaccination, only 64 and 67 percent of kidney transplant recipients showed neutralization against B.1.351 (β) and B.1.617.2 (δ)
COVID-19 Deaths Up for Kidney Waitlist Candidates, Transplant Recipients
11 percent of deaths in 2020 in kidney transplant-waitlisted candidates were attributed to COVID-19
Post-Acute Kidney Sequelae Studied in COVID-19 Survivors
Graded increase seen in risks for kidney outcomes according to the severity of the acute infection
Third COVID-19 Vaccine Dose May Prompt Response in Transplant Recipients
Third dose of mRNA-1273 vaccine induces serologic response in 49 percent of kidney recipients who did not respond after two doses
Hemodialysis Patients Have Antibody Response to COVID-19 Vaccine
But few kidney transplant recipients develop anti-spike SARS-CoV-2 antibodies after second mRNA vaccine dose
Excess Deaths Estimated for ESRD Patients During COVID-19
Excess deaths estimated at 8.7 to 12.9 per 1,000 ESRD patients, representing a total of 6,953 to 10,316 excess deaths
- Page 1 of 2
- 1
- 2